Nektar Therapeutics (NASDAQ:NKTR) reached a new 52-week high during trading on Tuesday . The company traded as high as $18.99 and last traded at $18.93, with a volume of 551,463 shares changing hands. The stock had previously closed at $18.45.

A number of research firms recently commented on NKTR. Zacks Investment Research downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 1st. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $21.00 price objective (up previously from $17.00) on shares of Nektar Therapeutics in a report on Friday, August 5th. Finally, Brean Capital reiterated a “buy” rating and issued a $18.00 price objective on shares of Nektar Therapeutics in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.40.

The stock’s 50-day moving average price is $16.93 and its 200-day moving average price is $14.78. The firm’s market capitalization is $2.60 billion.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.03. During the same quarter in the previous year, the company posted ($0.40) earnings per share. The business earned $32.77 million during the quarter, compared to analysts’ expectations of $34.17 million. The business’s quarterly revenue was up 44.6% on a year-over-year basis. Equities analysts predict that Nektar Therapeutics will post ($1.11) EPS for the current year.

In related news, CAO Jillian B. Thomsen sold 100,000 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $15.09, for a total transaction of $1,509,000.00. Following the sale, the chief accounting officer now owns 106,809 shares of the company’s stock, valued at approximately $1,611,747.81. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert Chess sold 5,000 shares of the firm’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $14.10, for a total value of $70,500.00. The disclosure for this sale can be found here.

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.